Skip to main content
logo
Bausch + Lomb Corporation (TSX:BLCO)
Canada flag Canada · Delayed Price · Currency is CAD
23.25
+0.80 (3.56%)
At close: Feb 6, 2026

Revenue by Geography

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18
U.S. and Puerto Rico Revenue
-2.41B1.93B
U.S. and Puerto Rico Revenue Growth
-24.77%14.10%
Total International Revenue
-2.38B2.21B
Total International Revenue Growth
-7.51%6.71%
Revenue (Total)
5.53B4.79B4.15B
Revenue (Total) Growth
15.43%15.56%10.03%

Revenue Breakdown

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18
Vision Care Revenue
2.87B2.74B2.54B
Vision Care Revenue Growth
4.71%7.71%7.34%
Surgical Revenue
876.00M843.00M767.00M
Surgical Revenue Growth
3.91%9.91%6.83%
Ophthalmic Pharmaceuticals Revenue
1.23B1.21B836.00M
Ophthalmic Pharmaceuticals Revenue Growth
1.90%44.62%22.76%
Revenue (Other)
554.51M--
Revenue (Total)
5.53B4.79B4.15B
Revenue (Total) Growth
15.43%15.56%10.03%

Revenue Breakdown 2

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18
Pharmaceuticals Revenue
1.03B969.00M618.00M
Pharmaceuticals Revenue Growth
6.30%56.80%32.05%
Devices Revenue
1.88B1.80B1.65B
Devices Revenue Growth
4.44%9.09%4.96%
OTC Revenue
1.81B1.72B1.61B
OTC Revenue Growth
4.81%7.01%10.27%
Branded and Other Generics Revenue
240.00M281.00M252.00M
Branded and Other Generics Revenue Growth
-14.59%11.51%2.86%
Total Product Revenue
4.96B4.77B4.13B
Total Product Revenue Growth
3.83%15.57%10.28%
Other Product Revenue
19.00M17.00M15.00M
Other Product Revenue Growth
11.77%13.33%-31.82%
Revenue (Total)
5.53B4.79B4.15B
Revenue (Total) Growth
15.43%15.56%10.03%

EBIT

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18
Vision Care Segment Profit
839.00M808.00M689.00M
Vision Care Segment Profit Growth
3.84%17.27%8.33%
Surgical Segment Profit
19.00M44.00M50.00M
Surgical Segment Profit Growth
-56.82%-12.00%19.05%
Ophthalmic Pharmaceuticals Segment Profit
180.00M256.00M241.00M
Ophthalmic Pharmaceuticals Segment Profit Growth
-29.69%6.22%18.72%
Corporate Segment Profit
-652.00M-614.00M-536.00M
Amortization of Intangible Assets
-270.00M-288.00M-240.00M
Net Other Expense
-28.00M-44.00M-74.00M
Operating Income (Other)
-7.22M--
Operating Income (Total)
80.78M162.00M130.00M
Operating Income (Total) Growth
-50.13%24.62%-37.20%

Capital Expenditures

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18
Vision Care Capital Expenditures
-116.00M
Vision Care Capital Expenditures Growth
-0.87%
Surgical Segment Expenditures
-26.00M
Surgical Segment Expenditures Growth
-8.33%
Ophthalmic Pharmaceuticals Capital Expenditures
-24.00M
Ophthalmic Pharmaceuticals Capital Expenditures Growth
--11.11%
Corporate Capital Expenditures
-15.00M
Corporate Capital Expenditures Growth
-66.67%

Key Performance Indicators

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18
Vision Care Revenue Change in Constant Currency
10.00%10.00%
Surgical Revenue Change in Constant Currency
11.00%7.00%
Ophthalmic Pharmaceuticals Revenue Change in Constant Currency
45.00%24.00%
Total Revenue Change in Constant Currency
17.00%12.00%
Updated Sep 30, 2025. Data Source: Fiscal.ai.